Viewing data from:

ATROMID-S

NDA

CLOFIBRATE | N016099 | WYETH AYERST LABORATORIES

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

API Supply Chain0 active DMFs4 inactive

0 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

MEDIMPEX NORTHAMERICA INCInactiveCLOFIBRATE

DMF 27101976

ACIC LTDInactiveCLOFIBRATE B/P/USP/NF

DMF 29761977

INDUSTRIA CHEMICA PRODOTTI FRANCIS SPAInactiveCLOFIBRATE USP

DMF 54071984

ORGAMOL SAInactiveCLOFIBRATE

DMF 58521985

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#002 — 500MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.